Jefferies analyst Biren Amin raised his price target for Neurocrine (NBIX) to $61 from $58 after surveying 50 U.S. doctors about the current and future Tardive Dyskinesia and Tourette's Syndrome treatment landscapes. The doctors estimated "significant uptake" for both Neurocrine's valbenazine and Teva's (TEVA) deutetrabenazine, but were more bullish on valbenazine, Amin tells investors in a research note. The analyst upped his estimated patient numbers and increased market share for valbenazine in Tardive Dyskinesia and keeps a Buy rating on Neurocrine.

Vanda Pharmaceuticals "announced that the Supreme Court denied Vanda's petition for a writ of certiorari in its HETLIOZ(R) Abbreviated New Drug Application litigation against Teva Pharmaceuticals USA, Inc., Apotex Inc. and Apotex Corp." CEO Mihael H. Polymeropoulos stated: "We are disappointed that the Supreme Court has decided not to hear our case and clarify the lower court standard for obviousness in patent law. However, we are pleased that our case has drawn attention to an area of law that has broad and significant implications in life sciences innovation."